U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Investra-24hs - 543610 - 12/28/2017
  1. Warning Letters

WARNING LETTER

Investra-24hs MARCS-CMS 543610 —

Recipient:
Investra-24hs

United States

Issuing Office:
Center for Drug Evaluation and Research

United States

 

  

Black HHS-Blue FDA Logo

 

 

 
 

 

TO:         Investra-24hs
 
FROM: The United States Food and Drug Administration

 
RE:        Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to    
              United States Consumers over the Internet   
 
DATE: December 28, 2017
WARNING LETTER
 
The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in violation of sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.
 
Unapproved New Drugs
 
As labeled, certain products offered for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products, as marketed through your websites, are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].
 
For example, your websites offer for sale “Generic Meridia (Sibutramine)” marketed as an “appetite suppressant, which is used in the short-term treatment of obesity….” Meridia (sibutramine) is an unapproved drug because there are currently no FDA-approved applications in effect for this product. Although Meridia was approved for use in the U.S. in 1997 for weight loss and maintenance of weight loss in obese people, it was voluntarily withdrawn from the U.S. market in December 2010, due to clinical trial data indicating an increased risk of heart attack and stroke.[1] In an FDA Safety Alert in October 2010, the Agency recommended that physicians stop prescribing Meridia to their patients and for patients to stop taking this medication due to severe adverse events associated with use of the product.
 
Misbranded Drugs
 
A drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if it fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purpose(s) for which it is intended (21 CFR 201.5). Prescription drugs, as defined in 503(b)(1)(A) of the FD&C Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
 
Because the aforementioned drug is a prescription product intended for condition(s) that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use this product safely for its intended use(s). Consequently, the labeling for this product fails to bear adequate directions for its intended use(s), causing it to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]. Because this drug is not approved in the U.S., it is also not exempt under 21 CFR 201.115 from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, your websites are causing the introduction of a misbranded drug into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. 
 
* * *
FDA is taking this action against Investra-24hs because of the inherent risk to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. 
 
This letter is not intended to identify all the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products that you market are in compliance with the FD&C Act and its implementing regulations.  You should take prompt action to correct the violations noted above as well as any other violations of the FD&C Act (which would include the offer for sale of all unapproved and/or misbranded drug products by your websites, not just the products noted above).  Failure to correct violations may result in FDA regulatory action, including seizure or injunction, without further notice.  
 
Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the violations set forth above and to prevent their recurrence. 
 
If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
 
Table of Websites:
Connecting URL
 
apotekudenrecept.com
pharmadiscount25.net
allpresciption.com
canadian-sells.com
7-rx.net
trustpillsnorx.com
euro-pharma365.net
medsonline-365.com
yourpharmanorx.com
rxpharma24-hs.com
rxpharma25-hs.com
sibutramine-weigthloss.com
zopiclone-insomnia.com
medsonline-365.net
goldpharma-24.com
onepharmatoday.com
rx-pharma24-hs.com
rxpharm24.com
openpharma4u.com
bestrxpills.net
pharmvnp.com
goldpharma24.com
trust-pharma24hs.com
rxonlinemedicines.com
super-rxstore.com
open24hs.net
pharmanow-24hs.com
sales-24hs.com
rx-pharma24.com
sales24-hs.com
365discountmeds.net
get-tramadol.com
medicineviagra.com
viagraedperfect.com
viagraonlinefreeships.com
  
 
Sincerely,
 
/S/
 
Thomas Christl
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration
 
 
 
 
 
 

[1] Withdrawal of Approval of a New Drug Application for Meridia, 75 Fed. Reg. 80061(Dec. 21, 2010). http://www.gpo.gov/fdsys/pkg/FR-2010-12-21/pdf/2010-31986.pdf [Accessed July 24, 2017]

 

 
Back to Top